← Wiki Index / Public Health & Global Health / Cholera
🏥 Public Health & Global Health

Cholera

Cholera is an acute, secretory diarrheal disease of the human small intestine caused by toxigenic strains of the comma-shaped Gram-negative bacterium Vibrio cholerae serogroups O1 and O139.

Cholera is an acute, secretory diarrheal infection of the human small intestine caused by ingestion of water or food contaminated with toxigenic strains of the comma-shaped, facultatively anaerobic Gram-negative bacterium Vibrio cholerae belonging to serogroups O1 or O139. Secreting cholera toxin (CT)—an AB5 ADP-ribosylating enterotoxin encoded by the lysogenic filamentous bacteriophage CTXφ—toxigenic V. cholerae constitutively activates adenylate cyclase inside intestinal crypt enterocytes, driving massive efflux of chloride (Cl−), bicarbonate (HCO3−), sodium (Na+), potassium (K+), and water into the gut lumen at rates reaching 500 to 1,000 mL per hour ("rice-water stool"). Without prompt fluid and electrolyte replacement, isotonic dehydration can progress within 4 to 12 hours to hypovolemic shock, metabolic acidosis, acute renal failure, and death (case fatality ratio >50% untreated versus <0.5% with oral and intravenous rehydration). Globally, cholera causes an estimated 1.3 to 4.0 million cases and 21,000 to 143,000 deaths annually across endemic deltas and humanitarian emergencies.

Bacteriology, Serogroups, and the CTXφ Bacteriophage Virulence Cassette

Divided Two-Chromosome Genome and Serogroup O1/O139 Classification

First observed microscopically by the Italian anatomist Filippo Pacini in Florence in 1854 (Vibrio cholerae Pacini 1854)—the same year British physician John Snow mapped the Broad Street pump outbreak in Soho, London, to establish waterborne epidemiology—and isolated in pure culture by Robert Koch in Alexandria and Calcutta in 1883–1884, V. cholerae is a halotolerant, curved rod (1.5–3.0 μm long by 0.5 μm wide) propelled by a single sheathed polar flagellum driven by a sodium-motive force (Na+) motor.

As revealed by the complete genome sequencing of V. cholerae El Tor strain N16961 in 2000 (Heidelberg et al., 2000), its 4.03-megabase (Mbp) genome is partitioned between two non-homologous circular chromosomes:

  • Chromosome 1 (2.96 Mbp): Carries the majority of essential housekeeping genes for DNA replication (oriC1 regulated by DnaA), transcription, translation, cell-wall biosynthesis, and the key pathogenicity islands (VPI-1 and CTXφ).
  • Chromosome 2 (1.07 Mbp): Originated as a captured megaplasmid (oriC2 regulated by RctB) and houses a 125-kbp superintegron (containing >170 gene cassettes) alongside specialized metabolic pathways for chitin utilization and environmental survival in brackish estuaries, where V. cholerae forms biofilms on the chitinous exoskeletons of calanoid and cyclopoid copepods (and can be transported mechanically on food by synanthropic vectors such as the house fly).

Although more than 200 serogroups of V. cholerae are distinguished by the structure of the O-antigen polysaccharide of their outer-membrane lipopolysaccharide (LPS), only strains carrying the CTXφ prophage within two serogroups cause epidemic and pandemic cholera:

  1. Serogroup O1: Divided into two biotypes—Classical (responsible for the fifth and sixth pandemics, 1881–1923, and now largely extinct in the wild) and El Tor (first isolated at the El Tor quarantine camp in the Sinai Peninsula in 1905 and responsible for the ongoing Seventh Pandemic since 1961, which resists polymyxin B, expresses VP-Voges-Proskauer positivity, and produces higher environmental persistence per clinical case). Each biotype is further subdivided by O-antigen methylation into two major serotypes: Ogawa (methylated terminal perosamine, antigens A and B) and Inaba (unmethylated terminal perosamine, antigens A and C), between which strains can switch during outbreaks via mutations in the methyltransferase gene wbeT.
  2. Serogroup O139 ("Bengal"): Emerged in late 1992 in Madras and across the Bay of Bengal when a Seventh Pandemic O1 El Tor strain acquired a 35-kbp O-antigen biosynthesis gene cluster and capsular polysaccharide via horizontal gene transfer, allowing it to evade pre-existing O1 mucosal immunity in adults.

Two-Step Horizontal Evolution: VPI-1 (TCP) and Lysogenic CTXφ Phage

As demonstrated by Matthew K. Waldor and John J. Mekalanos in 1996, a benign environmental V. cholerae strain evolves into an epidemic pathogen through the sequential horizontal acquisition of two cooperating genetic elements controlled by the master transcriptional cascade ToxRS / TcpPH → ToxT:

  1. Vibrio Pathogenicity Island-1 (VPI-1, 41.2 kbp): Encodes the Toxin-Coregulated Pilus (TCP, tcpA–tcpF), a Type IV bundle-forming pilus required for microcolony aggregation on the brush border of the human small intestine.
  2. Filamentous Bacteriophage CTXφ (6.9 kbp ssDNA genome): Encodes the cholera toxin operon (ctxAB). Crucially, the extracellular receptor used by CTXφ to infect V. cholerae is the Toxin-Coregulated Pilus (TCP) itself (alongside the inner-membrane TolQRA complex). Only after a V. cholerae strain acquires VPI-1 and expresses TCP pili can it be infected by CTXφ, which integrates site-specifically at the chromosomal dif recombination site via host XerCD recombinases to convert the bacterium into a toxigenic lysogen.
Genetic Element / FactorSize & Genomic LocusPrimary Encoded FactorsMechanistic Role in Pathogenesis
VPI-1 (Pathogenicity Island 1)41.2 kbp on Chromosome 1TCP (tcpA), ToxT (toxT), TcpPHBundle-forming intestinal colonization pilus; receptor for CTXφ phage
CTXφ (Lysogenic Filamentous Phage)6.9 kbp integrated at Chr 1/2 difCholera Toxin (ctxA, ctxB), Zot, AceAB5 ADP-ribosylating enterotoxin driving cAMP/CFTR Cl− secretion
VSP-1 & VSP-2 (Seventh Pandemic Islands)16 kbp & 26.9 kbp on Chromosome 1Cyclic oligonucleotide signaling (DncV), chemotaxisDiagnostic markers of Seventh Pandemic O1 El Tor lineage
SXT / R391 ICE (Integrative Conjugative Element)~100 kbp chromosomal islandsul2, dfrA1, strAB, floR, tetAConfers multidrug antimicrobial resistance in 7PET Wave 3 strains

Molecular Pathophysiology and the SGLT1 Basis of Oral Rehydration Therapy

Cholera Toxin (AB5) Endocytosis, Gsα ADP-Ribosylation, and CFTR Chloride Flux

Because V. cholerae is acid-sensitive, establishing infection requires ingesting a high inoculum (108 to 1011 organisms in healthy individuals, or 104 to 105 when gastric acid is buffered by food, hypochlorhydria, or proton-pump inhibitors) or ingesting hyperinfectious biofilm aggregates shed in fresh rice-water stool. Surviving vibrios swim through the intestinal mucus layer via mucinase/hemagglutinin protease (hapA) and polar flagellar motility, adhere to small-intestinal microvilli via TCP, and secrete the 84-kDa heterohexameric Cholera Toxin (CT = CTA + 5 CTB):

  1. GM1 Ganglioside Binding and Retrograde Trafficking: The pentameric B-subunit ring (CTB5, five 11.6-kDa monomers) binds with high avidity (Kd ≈ 10−10 M) to up to five molecules of monosialoganglioside GM1 on the apical lipid-raft membrane of enterocytes. The toxin-receptor complex undergoes endocytosis and retrograde vesicular transport through the Golgi apparatus to the lumen of the endoplasmic reticulum (ER).
  2. ER Dislocation and Gsα ADP-Ribosylation: Inside the ER, protein disulfide isomerase (PDI) reduces and unfolds the catalytic CTA1 subunit (~22 kDa) from the CTA2 tether, and CTA1 retrotranslocates through the Sec61 channel into the cytosol (escaping ubiquitination and proteasomal degradation because CTA1 contains only two lysine residues). Binding host ARF6-GTP allosterically activates CTA1, which transfers an ADP-ribose moiety from intracellular NAD+ onto Arg201 of the α-subunit of the stimulatory heterotrimeric G-protein (Gsα).
  3. Constitutive Adenylate Cyclase, cAMP, and CFTR Opening: Covalent ADP-ribosylation of Arg201 abolishes the intrinsic GTPase activity of Gsα, locking Gsα permanently in its active GTP-bound state. Active Gsα stimulates basolateral adenylate cyclase, elevating intracellular 3′,5′-cyclic AMP (cAMP) 100-fold. Elevated cAMP activates Protein Kinase A (PKA), which phosphorylates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) chloride channel in crypt cells (driving active Cl− and HCO3− efflux into the lumen) while inhibiting neutral Na+/H+ (NHE3) absorption in villus cells. Paracellular Na+, K+, and water follow osmotically, overwhelming colonic absorptive capacity and producing rice-water stool containing ~130 mmol/L Na+, 20 mmol/L K+, 100 mmol/L Cl−, and 45 mmol/L HCO3−.

Why Oral Rehydration Solution (ORS) Works: SGLT1 Cotransport

Crucially, cholera toxin does not destroy the brush-border architecture of the intestinal epithelium, nor does elevated cAMP inhibit the apical Sodium-Glucose Linked Transporter 1 (SGLT1), which couples the inward transport of 1 D-glucose molecule and 2 Na+ ions across the apical enterocyte membrane (driven by the basolateral Na+/K+-ATPase pump), pulling ~200–260 water molecules osmotically per cycle. Formulated physiologically in the 1960s and validated during the 1971 Bangladesh refugee crisis by David Nalin, Richard Cash, Norbert Hirschhorn, Dilip Mahalanabis, and colleagues, World Health Organization low-osmolarity Oral Rehydration Solution (ORS: 75 mmol/L Na+, 75 mmol/L glucose, 65 mmol/L Cl−, 20 mmol/L K+, 10 mmol/L citrate; total osmolarity 245 mOsm/L) harnesses intact SGLT1 cotransport to reverse dehydration orally in >90% of patients, while patients in severe hypovolemic shock (>10% body weight loss) receive rapid intravenous Ringer's lactate (100 mL/kg over 3–6 hours) plus a single dose of oral azithromycin or doxycycline to halve stool volume and vibrio shedding duration.

Recent Events

In October 2022, because global demand for killed whole-cell Oral Cholera Vaccines (OCV) exceeded the annual manufacturing capacity (~37–50 million doses) of the International Coordinating Group (ICG) emergency stockpile during simultaneous multi-country outbreaks, the ICG instituted a global suspension of the standard two-dose OCV regimen, pivoting reactive outbreak vaccination campaigns to a single-dose OCV strategy that provides 80%–85% short-term protection for 6 to 12 months in adults and children aged ≥5 years [7].

In 2022–2024, Seventh Pandemic Vibrio cholerae O1 El Tor (7PET Wave 3) resurgence expanded across more than 30 countries in Africa, the Eastern Mediterranean, South Asia, and the Caribbean—including Malawi, Mozambique, Haiti, Syria, the Democratic Republic of the Congo, Ethiopia, Sudan, Zambia, and Zimbabwe—driven by cyclonic flooding such as Cyclone Freddy in southeastern Africa in 2023, prolonged droughts, armed conflict, and fragile water and sanitation infrastructure that concurrently strained regional responses to mpox and poliomyelitis [6] [7]. Whole-genome phylogenomic tracking of the southeastern African epidemic demonstrated that imported South Asian 7PET sublineages carrying the SXT/R391 integrative conjugative element and gyrA/parC mutations displaced historic regional clones, driving national case fatality ratios above the 1% emergency threshold to reach 1.9%–3.2% [6].

In April 2024, to expand global vaccine manufacturing throughput and resolve the emergency stockpile bottleneck across 2024–2026, the World Health Organization granted prequalification to Euvichol-S, a simplified killed whole-cell OCV formulation comprising two inactivated V. cholerae O1 strains (formalin-inactivated Inaba El Tor and heat-inactivated Ogawa Classical) that achieved non-inferior vibriocidal seroconversion in Phase 3 randomized clinical trials while increasing production capacity by 35%–40% at lower unit cost [5].

In September 2026, the World Health Organization's annual global surveillance synthesis covering 2025 reported 451,499 cholera cases and 7,870 deaths across 47 countries: although reported case counts declined roughly 20% compared with 2024, recorded fatalities rose 30% to the highest annual total reported to WHO since 1999, with approximately 90% of cases and deaths concentrated in seven humanitarian-crisis nations (Angola, Bangladesh, the Democratic Republic of the Congo, Nigeria, South Sudan, Sudan, and Yemen) and more than one in five fatalities occurring outside health facilities [9].

Frequently Asked Questions

Why does plain drinking water fail to rehydrate a cholera patient, whereas adding glucose and salt succeeds?

In cholera, elevated intracellular cyclic AMP (cAMP) blocks the normal neutral sodium-chloride (NHE3/DRA) absorption channels in intestinal villus cells, so plain water or plain salt water drunk by a patient cannot be absorbed and simply passes out in the diarrhea. However, the apical SGLT1 sodium-glucose cotransporter is completely unaffected by cAMP. When a patient drinks low-osmolarity Oral Rehydration Solution containing equimolar glucose and sodium (75 mmol/L each), SGLT1 actively transports two Na+ ions and one glucose molecule together across the brush border into the enterocyte, generating an osmotic gradient that pulls water and electrolytes from the gut lumen back into the bloodstream.

How did a harmless brackish-water bacterium become the agent of pandemic cholera?

Most environmental Vibrio cholerae strains living on copepod shells in coastal estuaries lack cholera toxin and cannot cause pandemic disease. Pandemic potential evolved via a two-step horizontal gene transfer cascade: first, an ancestral O1 strain acquired the VPI-1 pathogenicity island, which encodes the Toxin-Coregulated Pilus (TCP) needed to colonize the human small intestine; second, because the filamentous bacteriophage CTXφ uses the TCP pilus as its surface receptor to enter the bacterium, only TCP-positive strains could be infected and lysogenized by CTXφ, which integrated the ctxAB cholera toxin genes permanently into the bacterial chromosome.

Why are people with Type O blood at higher risk of severe cholera dehydrating shock, yet less likely to die of malaria?

Epidemiological cohorts in the Ganges Delta (where cholera has been endemic for centuries) show that although individuals of all ABO blood groups are equally likely to become infected with V. cholerae O1, individuals with blood group O are roughly twice as likely to develop severe, life-threatening cholera gravis. Crystallographic and enteroid studies demonstrated that the CTB5 subunit of cholera toxin binds not only to GM1 gangliosides, but also via a secondary binding pocket to fucosylated H-antigen oligosaccharides (which are unmodified on the intestinal epithelial glycoproteins of blood group O individuals, whereas A and B transferases sterically cap the H antigen in blood groups A, B, and AB). Consequently, natural selection by cholera in the Ganges Delta drove the frequency of the Type O allele down to the lowest levels in the world, whereas in Sub-Saharan Africa Plasmodium falciparum malaria selected for Type O blood because the parasite's PfEMP1 rosetting adhesins bind A and B antigens.

References

  1. Waldor, M. K., & Mekalanos, J. J. (1996). Lysogenic conversion by a filamentous phage encoding cholera toxin. Science, 272(5270), 1910–1914. https://doi.org/10.1126/science.272.5270.1910
  2. Heidelberg, J. F., Eisen, J. A., Nelson, W. C., Clayton, R. A., Gwinn, M. L., Dodson, R. J., Haft, D. H., Hickey, E. K., Peterson, J. D., Umayam, L., Gill, S. R., Nelson, K. E., Read, T. D., Tettelin, H., Richardson, D., Ermolaeva, M. D., Vamathevan, J., Bass, S., Qin, H., ... Fraser, C. M. (2000). DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature, 406(6795), 477–483. https://doi.org/10.1038/35020000
  3. Harris, J. B., LaRocque, R. C., Qadri, F., Ryan, E. T., & Calderwood, S. B. (2012). Cholera. The Lancet, 379(9835), 2466–2476. https://doi.org/10.1016/S0140-6736(12)60436-X
  4. Clemens, J. D., Nair, G. B., Ahmed, T., Qadri, F., & Holmgren, J. (2017). Cholera. The Lancet, 390(10101), 1539–1549. https://doi.org/10.1016/S0140-6736(17)30559-7
  5. Song, K. R., Lim, J. K., Park, S. E., Saluja, T., Cho, S.-I., Wartel, T. A., & Lynch, J. (2024). Safety and immunogenicity of a simplified oral cholera vaccine (Euvichol-S) compared with Euvichol-Plus in healthy Nepalese participants: a phase 3, randomised, observer-blind, non-inferiority trial. The Lancet Global Health, 12(5), e826–e836. https://doi.org/10.1016/S2214-109X(24)00059-7
  6. Chaguza, C., Chibwe, I., Chaima, D., Musicha, P., Ndeketa, L., Kasambara, W., Mhango, C., ... & Cornick, J. E. (2024). Genomic insights into the 2022–2023 Vibrio cholerae outbreak in Malawi. Nature Communications, 15(1), 6291. https://doi.org/10.1038/s41467-024-50484-w
  7. World Health Organization. (2024). Cholera Fact Sheet and Global Resurgence Surveillance. https://www.who.int/news-room/fact-sheets/detail/cholera
  8. Thomson, F. (2023). Responding to the global cholera pandemic. Bulletin of the World Health Organization, 101(4), 234–235. https://doi.org/10.2471/blt.23.020423
  9. World Health Organization (2026). "WHO reports latest global trends in cholera, meningitis and plague" (29 September 2026; summarizing 2025 global surveillance data). https://www.who.int/news/item/29-09-2026-who-reports-latest-global-trends-in-cholera--meningitis-and-plague
🧬 Support Open Science
Explore interactive science games on LowKey Games or browse scientific apparel & accessories in the CRV Science Shop.
💡 Spot an inaccuracy or have primary literature to expand this article?
Submit a citation or revision note using your shared CRV Science / LowKey Games profile ID.
Suggest Revision